NCT01515657View on ClinicalTrials.gov

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

PL2200 Aspirin Capsules

325 mg aspirin; once per day for 3 days

DRUG

Immediate-Release Aspirin Tablets

325 mg aspirin; once per day for 3 days

DRUG

Enteric-coated aspirin caplets

325 mg aspirin; once per day for 3 days

Trial Locations (1)

45212

MedPace Clinical Pharmacology, Cincinnati

Sponsors

Lead Sponsor

PLx Pharma
All Listed Sponsors
lead

PLx Pharma

INDUSTRY